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INTRODUCTION
Aberrant systemic arterial supply to the normal lung (ASANL) is a rare disease. Although most patients with ASANL are asymptomatic, the presenting symptoms are cardiac murmur in childhood, and recurrent hemoptysis, dyspnea on exertion, and congestive heart failure in adults (1) . Diagnosis is relatively easy with chest computed tomography (CT) (1, 2) . However, treatment options vary, including surgical resection of the involved lung and surgical ligation of the aberrant artery, and endovascular treatment has been recently introduced (3) . We reported a case of a 24-year-old man with ASANL who was treated by the endovascular method. In addition, we reviewed the relevant literature.
CASE REPORT
A 24-year-old man presented with dyspnea on exertion and intermittent blood-tinged sputum. Dyspnea had started in his childhood, and was aggravated with intermittent blood-tinged sputum for the past 2-3 years. He was a social smoker (1 cigarette a day), and had no specific history.
Chest CT showed large tortuous vessels arising from the descending thoracic aorta in the basal segments of the left lower lobe (Fig. 1A) . The largest diameter of the vessel at the origin was 1.4 cm. There were no findings to suggest hypertrophied systemic artery associated with chronic inflammation. In contrast to scimitar syndrome, the lungs were not hypogenetic, and the left lower lobar pulmonary vein was dilated and normally drained to the left atrium (Fig. 1B) . Courses of the bronchial tree were normal, and thickening of the interstitial markings with groundglass opacities were observed. These findings were compatible A 24-year-old man presented with dyspnea on exertion and intermittent blood-tinged sputum. He was diagnosed with aberrant systemic arterial supply to the normal lung (ASANL) based on the results of imaging studies. The patient was successfully treated with transarterial embolization using coils and a vascular plug and his symptoms disappeared during the follow-up. Herein, we reported the imaging findings of ASANL, differential diagnoses, and its treatment options. In addition, we reviewed the relevant literature.
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J Korean Soc Radiol 2017;76(6):395-402 Fig. 1 . Aberrant systemic arterial supply to the normal lung treated with transarterial embolization in a 24-year-old man. A, B. Initial chest CT. Volume rendering image (A) shows a 14-mm-sized, large tortuous vessel (arrow) arising from the descending thoracic aorta and supplying the basal segments of the left lower lobe. On lung window setting image, thickening of the interstitial markings with ground glass opacities, consistent with pulmonary congestion, was noted in the left lower lobe; courses of the bronchial tree in both lungs were normal (not shown). On coronal reformatted image (B), the left lower lobar pulmonary vein is dilated, as compared to the right lower lobar pulmonary vein (curved arrow), and normally drains to the left atrium. C. Images of conventional angiography (upper panel) and transarterial embolization (lower panel). Left pulmonary angiography shows hypoplasia or absence of the left lower pulmonary artery and decreased perfusion in the left lower lung zone (black arrows). Initial thoracic aortography and selective angiography of the aberrant systemic artery reveal an aberrant systemic artery (white arrows) arising from the descending thoracic aorta and supplying the left lower lung zone. On delayed phase, the enlarged left lower pulmonary vein (open arrow) that drains to the left atrium, is observed. On post-embolization aortography, the aberrant systemic artery is no longer visualized, and hypertrophied left bronchial artery (curved arrow) with arteriovenous shunt in the left lower lung zone, which was not revealed on the initial thoracic aortography, is observed. The left bronchial artery was selected, and embolization was conducted using microcoils and gelfoam particles. On final post-embolization aortography, the aberrant systemic artery and the hypertrophied bronchial artery are obliterated. D. Follow-up chest CT image at 4 months after treatment. On the coronal reformatted image after treatment, the left lower lobar pulmonary vein is decreased in diameter. ; Alicon Pharm SCI&TEC Co., Ltd., Hangzhou, China). After embolization, the hypertrophied left bronchial artery was not observed (Fig. 1C) .
The patient complained of chest pain, fever, and chills for 6 days, which improved with supportive care. One week after TAE, his symptoms disappeared and he was discharged.
The patient was asymptomatic during the 1-year follow-up.
Follow-up chest CT at 4-months post-TAE showed decreased dilation of the distal branches of the ASA, and decreased size of the left lower lobar pulmonary vein (Fig. 1D) . A rare case of ASANL with two feeders including a normal systemic artery and ASA supplying the affected lung zone was reported (4). Unlike previously reported ASANL cases, we detected a newly developed hypertrophied bronchial artery soon after the ASA-embolization. Similar phenomena have been reported in the literature on embolization of pulmonary arteriovenous malformations (PAVMs) (8, 9) . In our case, the hypertrophied bronchial artery was possibly a preexisting lesion exaggerated by relative ischemia, or a new lesion caused by procedure-related local ischemia.
It is likely that the bronchial artery to the involved area underwent compensatory hypertrophy to preserve tissue perfusion. As reported in PAVMs, a hypertrophied bronchial artery can cause recurrent hemoptysis, and therefore, requires treatment. In our patient, the proximal portion of the suddenly developed bronchial artery was embolized with coils and large-diameter gelfoam particles to preserve tissue perfusion through collaterals and minimize the risk of ischemic injury.
Post-embolization syndrome is the most common complication of TAE of ASANL, and can be controlled conservatively.
J Korean Soc Radiol 2017;76(6):395-402 Table 1 Other reported complications included recurrent bleeding due to developed collaterals or residual arterial supply, and some respiratory symptoms, which were successfully treated. Along with pulmonary infarction, secondary infection and fistula are theoretically possible, but have not been reported to date (10).
Long-term results after TAE for ASANL remain unclear. Previous reports indicate that patients show improvement during the follow-up periods ranging from 6 months to 6 years. Additional long-term studies are clearly required.
Our patient was successfully treated with TAE. Brillet et al.
(9) reported development of a systemic collateral supply after embolotherapy of PAVM. They showed that enlargement of a systemic artery was observed more frequently in patients with clinical and/or radiological features suggesting post-treatment lung infarction, than in those without these features. Although our patient has been asymptomatic for 1 year, close and longterm follow-up is required.
